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Background: The current maintenance dose (10,000 AUeq/monthly) of a subcutaneous allergoid for house dust
mite (HDM) immunotherapy has previously shown significant clinical efficacy in patients with HDM induced allergic
rhinitis or rhinoconjunctivitis. In order to comply with the 2009 EMA guidelines on immunotherapy products, a
study was conducted to evaluate the safety, tolerability and short-term treatment effects of up-dosing regimens
with high doses (up to 40,000 AUeq) of allergoid HDM immunotherapy.
Methods: In total 48 patients with HDM-allergic rhinitis or rhinoconjunctivitis (29 M/19 F; 18–53 years) were
included and enrolled into one of three up-dosing regimens (1:4:4): 1) a regular regimen with up-dosing to 40,000
AUeq followed by two maintenance doses (total duration 17 weeks), 2) an intermediate regimen (14 weeks) or 3) a
fast regimen (11 weeks). Safety and tolerability were evaluated by monitoring of early and late local reactions and
systemic reactions. In addition, short-term effects were assessed by conjunctival provocation test (CPT) and levels of
serum allergen-specific IgE, IgG and IgG4.
Results: Thirty-nine patients completed the study according to protocol. No early local reactions occurred. Late
local reactions (LLR) were observed in 12% of the injections. In total, 31 systemic reactions, all grade 1, were
reported of which two needed oral antihistamine treatment. No grade 2 or higher systemic reactions were
observed. Six patients (15%) did not reach the highest dose due to LLR and/or systemic reactions needing
antihistamines (20% in the regular regimen, 16% in the intermediate regimen and 13% in the fast regimen). At the
end of the study, an improvement in the CPT was observed in 82.1% of patients, indirectly indicating an early
treatment effect at the current dose and higher doses. In addition, IgG4 immunoglobulin levels were significantly
increased in all groups following treatment.
Conclusions: In this open-label study, allergoid HDM immunotherapy in doses up to 40,000 AUeq was generally
well tolerated and no clinically relevant safety issues were identified. In the safety aspects of the three up-dosing
regimens no clinically relevant differences were encountered. Therefore, these dose ranges and up-dosing regimens
can be safely included in future dose-finding efficacy studies.
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Immunotherapy (IT) with mite extracts is a well-
established treatment for patients suffering from allergic
rhinoconjunctivitis and/or asthma caused by house dust
mite (HDM). Apart from being safe and effective in the
treatment of allergic airway disease [1,2], IT has been
shown to reduce the development of asthma as well as
the onset of new sensitizations in younger patients [3-5].
Traditionally, aqueous extracts have been used for
subcutaneous IT. However, soluble proteins can induce
severe local and/or systemic allergic adverse reactions
upon injection. With the introduction of aluminium hy-
droxide into allergen vaccines, the proteins are adsorbed
to a depot. As a result, allergens are slowly released into
the tissue during a longer period of time and thereby re-
ducing the occurrence of adverse reactions [6,7]. Modifi-
cation of the allergen extracts by glutaraldehyde further
reduced the risk of adverse reactions without comprom-
ising the immunogenic properties. Several studies have
shown that clinical efficacy is retained using modified al-
lergen extracts and that such preparations are consid-
ered safer than non-modified allergen extracts [8-10].
The product formulation currently under investigation
is a suspension of a glutaraldehyde-modified allergen ex-
tract from HDM adsorbed onto aluminium hydroxide.
In a previous placebo-controlled study, significant clin-
ical efficacy of one dose strength (10,000 AUeq) of this
product was demonstrated in terms of improvements in
symptom and medication scores in patients with HDM-
allergy after 1 year of treatment [11]. Overall, the prod-
uct was well tolerated.
According to the current EMA guidelines on the clin-
ical development of IT products [12], dose tolerability
studies should be completed before dose-finding efficacy
studies can be performed. Accordingly, products should
be tested at different doses to provide preliminary data
on safety and tolerability with regard to the maximum
tolerated dose and a suitable dose escalation scheme.
Therefore, a dose tolerability study was conducted using
three different up-dosing regimens, all ending at a 4-fold
higher dose (40,000 AUeq) compared to the previous
study. The primary outcome of the study was the pro-
portion of patients reaching the highest dose. On an ex-
ploratory basis, the short-term treatment effects were
investigated by the conjunctival provocation test (CPT)
and the serum immunoglobulin (Ig) levels.
Methods
This was a multicentre, open-label, parallel dose, tolerabil-
ity study with three up-dosing regimens. The study was
performed in 6 German centres. All patients were evalu-
ated during a screening visit to assess their baseline condi-
tion, including a conjunctival provocation test and baseline
serum immunoglobulin levels. Safety and tolerability wereevaluated throughout the study. Short-term effects were
assessed by CPT and serum Ig levels after patients received
6 doses in the up-dosing regimen and at the end of the
study.Patients
Patients, aged 18 years or older, suffering from allergic rhin-
itis or rhinoconjunctivitis related to house dust mites for at
least 2 years, with or without concomitant, clinically stable,
mild asthma (FEV1 >70% of predicted) were screened.
As verification of the clinical history, sensitizations of all
patients were confirmed by a positive (≥ 3 mm mean wheal
response) skin prick test (SPT) to HDM (Dermatophagoides
pteronyssinus (Der p) and/or Dermatophagoides farinae
(Der f)), a positive CPT to HDM allergen (dose ≤ 10.000
SQ-E/ml), and a positive specific serum IgE test (ssIgE >
0.7 U/ml) for HDM. The main exclusion criteria com-
prised clinically unstable or more severe asthma (FEV1
≤70%), any co-sensitization i.e., a positive SPT (≥ 3 mm)
to other aero-allergens than HDM if accompanied by
clinical symptoms at the time of inclusion. Patients
treated with HDM-IT within the last 5 years or other IT
at the time of enrolment were excluded from participa-
tion. During the study, patients were allowed to use anti-
histamines or other rescue medication as restrictive as
possible. To reduce effects of allergy medication on the
study parameters, corticosteroids and antihistamines were
not allowed 3 days before the CPT, and antihistamines
were not allowed 24 hours before and after IT injection.
Eligible patients were sequentially allocated (n=5 / n=20 /
n=20) to one of the dose regimens starting with the
slowest regimen.
The study protocol (EudraCT number 2008-006261-81)
was approved by the relevant Ethics Committees (lead
Ethics Committee: LAGeSo, Berlin, Germany) and all pa-
tients signed an informed consent form before participation.Investigational product and dosing schedules
Patients were allocated (1:4:4) to one of three up-
dosing regimens (Figure 1) of subcutaneous immunother-
apy (SCIT), consisting of a standardized suspension of
glutaraldehyde-modified allergoid extract from a mixture
of Dermatophagoides pteronyssinus and Dermatophagoides
farinae (1:1) adsorbed onto aluminium hydroxide
(PURETHALW Mites, 20,000 AUeq/ml, HAL Allergy BV,
Leiden, The Netherlands, containing major allergen equiv-
alents of 14.0 μg/ml group 1, and 20.0 μg/ml group 2,
measured by ELISA in the extract prior to modification
and adsorption on aluminium hydroxide).
During up-dosing, SCIT was administered at weekly in-
tervals until the maintenance dose was reached (40,000
AUeq, 2 ml) or no higher dose could be tolerated (see up-




















Figure 1 Up-dosing and maintenance phase of the different dosing regimens.
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in all three treatment regimens.
Up-dosing rules
If the local (early or late) reaction at the injection site
was too intense (swelling > 5 cm and ≤ 8 cm), the same
dose was repeated. If the swelling was > 8 cm, the next
dose was reduced by one step. If that dose was well tol-
erated, the dose was increased one week later until the
maintenance dose was reached. Patients were allowed to
receive 4 extra doses to the schedule before reaching the
maintenance dose, with a maximum of 2 equal doses in
succession. If the patient then still had not reached the
intended maintenance dose, the patient was kept on the
highest dose reached as the maintenance dose. For mild
to moderate systemic reactions (immediate or late) re-
quiring treatment with antihistamines and/or epineph-
rine, the next dose was reduced by one step in the
schedule and the patient was kept on this dose as the
maintenance dose.
Safety and tolerability (clinical evaluations)
Tolerability of the immunotherapy was evaluated by
early and late local reactions (i.e., swelling and redness),
and systemic reactions after injection. The local reac-
tions were classified into ≤ 5 cm or > 5 cm. As a criter-
ion of tolerability, the maximum number of injections
inducing a local swelling of > 5 cm was pre-set on 20%
based on expert opinions in daily practice. The systemic
reactions were graded into five categories according to
Malling et al. [13]. Early reactions were recorded by the
investigator: i.e., local reactions within 15 minutes after
injection and systemic reactions within 30 minutes.
Safety was further evaluated by assessment of vital
signs, blood parameters and ECG recording before the
start of treatment and at the end of study. If stable, pa-
tients were sent home 30 minutes after injection. All pa-
tients were instructed to fill out a diary to record latelocal and systemic reactions and any other adverse event
occurring after they had left the clinic.
Conjunctival Provocation Test (CPT)
A titrated CPT with an aqueous solution of HDM allergen
was performed at baseline, at scheduled visit 8 (i.e., one
week after reaching 10,000 AUeq, 20,000 AUeq or 40,000
AUeq for the respective dosing regimens), and at the end
of study (i.e., two weeks after receiving two maintenance
doses, for all regimens). The CPT was performed according
Riechelmann et al. [14]. Briefly, the test started with 10
SQ-E/ml (ALK-lyophilisiert HDM SQ Provokationstest,
ALK-Scherax, Wedel, Germany) and continued with 100,
1000, 10,000, and 100,000 SQ-E/ml until a positive reac-
tion (itching, redding and discharge) grade II or higher
was obtained [15]. To relieve the reaction, patients
received a topical antihistamine immediately after
completion of the test. The concentrations were pre-
pared on the study site from the stock solution of
100,000 SQ-E/ml on the day of the test. Topical/oral
corticosteroids and topical/oral antihistamines were not
allowed 3 days before the test.
Immunoglobulins
Before the start of treatment and at the end of study a
blood sample was taken from the patients to quantify spe-
cific IgE and specific IgG (IgG and IgG4 subtype) to HDM
and to the major allergens Der p 1, Der p 2, Der f 1, and
Der f 2 by ImmunoCAP analysis. The ImmunoCAP ana-
lysis was performed according to instructions of the manu-
facturer (Thermo Fisher Scientific, Uppsala, Sweden).
Statistical analysis
Descriptive statistics were performed for all safety and
tolerability data. The analysis was performed for all up-
dosing regimens combined and for each single regimen
separately. Since the main outcome parameter of this
study was the safety and tolerability of the up-dosing
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protocol was essential. Therefore the primary analysis
was performed on the per protocol (PP) population.
The analysis of the parameters to assess the short-
term treatment effect had an exploratory character. For
all these parameters, a Wilcoxon Signed Rank has been
applied, if the pre-post-difference in each regimen dif-
fered significantly from 0. To test if the pre-post-differ-
ences between pairs of regimens differed significantly
from each other a Wilcoxon rank-sum-test was used. A
significant difference was concluded for all p-values
below 0.05. For the analysis of the CPT, the allergen




Forty-eight patients were enrolled in the study and re-
ceived study medication. Nine patients were excluded
from the PP population; 3 patients due to inability to
follow the recommended up-dosing regimen, 2 patients
due to regular need of antihistamines, 3 patients with-
drew their consent and 1 patient was lost to follow-up.
Only one patient discontinued the study because of ad-
verse events, occurring after the first 3 doses, all with
swellings > 5 cm of mild intensity. This patient was not
excluded from the PP population. Characteristics at
baseline from enrolled and PP patients are outlined in
Table 1.
Tolerability
Thirty-nine patients completed the study PP and re-
ceived 440 subcutaneous injections of HDM immuno-
therapy. No early local reactions (ELR; swelling > 5 cm)
occurred. Late local reactions (LLR; swelling > 5 cm)
were observed (see Table 2) in 12% of the injections (7%
in the regular regimen, 11% in the intermediate regimen
and 16% in the fast regimen). Measurements of skin
redness showed similar results (data not shown). In total,
31 systemic reactions (early and late), all grade 1, were
reported of which two needed oral antihistamine treatmentTable 1 Baseline characteristics of safety and per protocol pa
Safety population
Regular Intermediate Fast
Patients (n) 6 21 21
Mean age ± SD (yrs) 27.5 ± 4.9 32.1 ± 11.4 31.2 ± 10
BMI ± SD (kg/m2) 27.5 ± 5.9 24.4 ± 3.5 26.7 ± 6.2
Patients with other allergies n (%) 5 (83.3%) 12 (57.1%) 12 (57.1%
SPT HDM D. pter ± SD (mm) 6.5 ± 3.1 6.6 ± 2.7 7.4 ± 4.5
SPT HDM D. far ± SD (mm) 7.8 ± 2.6 7.1 ± 1.9 7.0 ± 3.9
ssIgE ± SD (U/ml) 16.0 ± 19.7 23.4 ± 23.8 26.2 ± 28(see Table 2). In 12 cases presenting with grade 1 reactions
also a LLR occurred. No grade 2 or higher systemic reac-
tions were observed. Fifteen percent of patients (6 out of
39, see Figure 2) did not reach the highest dose due to
LLR and/or systemic reactions needing antihistamines
(20% in the regular regimen, 16% in the intermediate regi-
men and 13% in the fast regimen). The number and per-
centage of patients that reached the highest dose are
presented in Table 2. The majority of patients (11 out of
15) in the fast dosing regimen had no or only up to two in-
jections giving rise to a LLR before achieving the highest
dose.
Safety
Safety results are presented for the safety population,
which consisted of 48 patients that received any study
medication. In all three regimens, the majority of the
AEs was assessed as at least possibly related to treatment
and being of mild intensity (82.8% overall; regular regi-
men: 69.0%, intermediate regimen: 94.8%, fast regimen:
74.7%). In 17.2% of cases the AE was reported with
moderate intensity and no severe AEs were reported.
The most commonly reported adverse event was injec-
tion site swelling, which occurred in 66.7% of the pa-
tients. Other frequently reported related events included
nasopharyngitis (33.3%), headache (27.1%), arthralgia
and injection site pain (both 14.6%). Most of the adverse
events occurred during the up-dosing phase. The pattern
of adverse events was similar for all three up-dosing
regimens.
No clinically relevant changes in safety laboratory
values were observed following treatment except for one
patient in the regular up-dosing regimen. This patient
had an increased level of ALAT (75 U/l; normal upper
range value: 45 U/l) at the end of the study. No clinically
relevant deviations in systolic and diastolic blood pres-
sure, heart rate and ECG were observed. No differences
were detected for any of these parameters among the
three treatment regimens.
A data safety monitoring board (DSMB) evaluated all
reported reactions of all immunotherapy injections on atients per up-dosing regimen
Per protocol
Overall Regular Intermediate Fast Overall
48 5 19 15 39
.6 31.2 ± 10.4 27.2 ± 5.5 31.8 ± 11.3 33.1 ± 10.4 31.7 ± 10.3
25.8 ± 5.2 27.7 ± 6.6 24.5 ± 3.4 26.7 ± 5.9 25.8 ± 4.9
) 29 (60.4%) 4 (80%) 10 (52.6%) 9 (60.0%) 23 (59.0%)
6.9 ± 3.6 7.0 ± 3.2 6.6 ± 2.8 8.0 ± 5.2 7.2 ± 3.9
7.1 ± 3.0 8.2 ± 2.8 7.0 ± 1.9 7.2 ± 4.4 7.2 ± 3.2
.2 23.7 ± 25.1 17.1 ± 21.8 24.5 ± 24.7 34.1 ± 29.9 27.3 ± 26.5
Table 2 Late local and systemic reactions per injection and per patient in each up-dosing regimen and the highest
dose reached









n (%) patients [95% CI]
Regular (n=5) 73 5 (7) 2 (40.0) 4 (5) 4 (80.0) 4 (80.0) [44.9-100]
Intermediate
(n=19)
221 24 (11) 11 (57.9) 23 (10) 9 (47.4) 16 (84.2) [67.8-100]
Fast (n=15) 146 23 (16) 10 (66.7) 4 (3) 3 (20.0) 13 (86.7) [69.5-100]
Overall (n=39) 440 52 (12) 23 (59.0) 31 (7) 16 (41.0) 33 (84.6) [73.3-95.9]
LLR= late local reaction (swelling > 5 cm), SR= systemic reaction (grade 1, early and late), CI=confidence interval.
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were issued by the DSMB.
Short-term treatment effects
Short-term treatment effects of HDM immunotherapy
were assessed by means of two surrogate efficacy markers:
i.e., the CPT and serum levels of allergen specific IgG
and IgE.
The mean lowest concentration that induced a posi-
tive (grade II) conjunctival reaction to HDM allergen
solution after 6 doses (visit 8) and at the end of study
(i.e., two weeks after receiving the last maintenance
dose) were increased compared to the mean lowest con-
centration one week before treatment (data not shown).
If during a CPT, a patient tolerated a higher dose of the
HDM allergen solution after HDM immunotherapy (i.e.
less sensitive); this was regarded as a sign of efficacy.
After 6 doses, 30 out of the 39 PP patients (76.9%,
p<0.05) were less sensitive to the CPT. At the end of the
study, an improvement was observed in 32 patients
(82.1%, p<0.0001). CPT changes in threshold concentra-
tion for the 3 up-dosing regimens are shown in Figure 3.
Following treatment, all specific serum IgG4 levels
were increased in all treatment groups. The different





















Figure 2 Percentage of patients per regimen reaching a certain dose.up-dosing regimens combined. IgG4 was raised by a fac-
tor 25.7 for Der p and by a factor 20.9 for Der f. An
overview of the specific serum immunoglobulin levels
for all regimens combined is given in Table 3. Between
the three up-dosing regimens, there was no significant
difference in the change in immunoglobulin levels from
baseline.
Discussion
D. pteronyssinus and D. farinae are the most common
HDM and are among the most widespread sources of
indoor allergens worldwide. These species are very
common in humid regions, where most allergic individuals
are sensitized to HDM [16].
In this study, the safety and tolerability as well as explora-
tory short-term effects of three different up-dosing regimens
with high doses of allergoid HDM SCIT have been evalu-
ated in patients with allergic rhin(oconjunctiv)itis to HDM.
The study had an open-label, parallel-dose, multicentre
design. Patients received HDM immunotherapy with a
mixture of 50% Dermatophagoides pteronyssinus and
50% Dermatophagoides farinae (20,000 AUeq/ml) by
means of subcutaneous injections according to a regular,
an intermediate or a fast regimen, reaching a maximum







































































Figure 3 Improvement in conjunctival provocation test (CPT) after 6 doses and at end of study.
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39) did not reach the maximum dose of 40,000 AUeq
due to late local reactions (swelling > 5 cm) or systemic
reactions. No early local reactions of > 5 cm occurred
and overall 12% of injections gave rise to late local reac-
tions of > 5 cm within 24 hours after injection. These
numbers are comparable with the overall numbers of
large local reactions found in other SCIT studies with
aluminium hydroxide adsorbed HDM extracts [17,18].
The highest percentage (16%) was found in the fast regi-
men group. However, in none of the up-dosing regi-
mens, the number of injections inducing a local swelling
of > 5 cm exceeded 20%, which was pre-set as a criterion
of tolerability.
A general risk of immunotherapy with higher allergen
extract doses is a potential increase in adverse reactions,
particularly systemic ones [19]. In this study, only grade 1
systemic reactions (7% overall) were observed and no sys-
temic reactions of grade 2 or higher. In accordance with a
previous study, most systemic reactions occurred below
the dose of 10,000 AUeq and did not require treatment
[11]. A study by Schubert et al. [17] revealed systemic re-
actions in 4.6% of cases following weekly up-dosing with
standardized aluminium hydroxide-adsorbed HDM im-
munotherapy. These reactions were mostly grade 1–2 and
in 0.7% of cases grade 3 [17]. An overview study on side-
effects of different allergen-specific SCIT with aluminium
hydroxide adsorbed extracts demonstrated that in 1%
grade 4 systemic reactions occurred (in 50% of cases a 9.8
μg Der p extract was involved) [19]. Grade 2 or higher
systemic reactions are not frequently reported during im-
munotherapy and therefore, a slight increase in the occur-
rence of these types of reactions would possibly remain
unnoticed in our limited study population. In contrast,
substantial increases in systemic reactions would even be
observed in small groups (20 patients per arm). Our study
did not show any severe reactions, suggesting at least that
higher doses of the allergoid HDM immunotherapy aresafe and well tolerated. Subsequent studies in larger popu-
lations are needed to confirm these findings.
When comparing the local and systemic reactions and
the other adverse reactions between the up-dosing regi-
mens, no clear difference in safety and tolerability was
observed. Therefore, all up-dosing regimens appeared safe
and were well tolerated. Short-term treatment effects were
assessed by two surrogate outcome parameters: i.e., the
CPT and the serum Ig levels, comparing the pre- versus
post-treatment changes.
The CPT results at the end of treatment showed an
improvement in the threshold concentration in 82.1% of
the per protocol patients. Increase of threshold is gener-
ally interpreted as a measure of improvement [20]. Im-
provements were noted in 76.9% of the per protocol
treated patients already after approximately 6 doses in
all up-dosing regimens. In a previous study with a lower
dose of this product (10,000 AUeq) 51% improvement in
CPT was observed after 12 months [11]. This previous
study was conducted in a similar patient population, but
included a placebo group that improved by 30%. The lar-
ger number of patients in the current study showing im-
provement in CPT after shorter treatment may be the
result of higher doses of allergoid HDM immunotherapy.
However, this needs to be confirmed.
Following treatment, HDM-specific serum Ig levels were
increased in all dosing groups compared to pre-treatment
levels. These findings indicate that treatment with high
doses of allergoid HDM immunotherapy induces an
immunological response within a short period of time.
Patients who failed to reach the highest maintenance
dose had an overall lower immunological response
compared to patients reaching the highest dose of
40,000 AUeq. The increase of IgG4 Der p levels was
higher compared to that found in the previous study
using the 10,000 AUeq dose (post-pre ratio of 6.6 in the
previous study and 25.7 in the current study) [11].
Similarly, this may be the result of the higher allergoid
Table 3 Specific serum immunoglobulins before and after treatment and the post/pre ratios for the different regimens
Regimen
Immunoglobulin Visit Slow Interme-diate Fast Overall
IgE Der p (kUA/l) Pre-T 13.0 ± 17.6 16.8 ± 18.5 36.0 ± 62.9 23.4±41.1
Post-T 46.3 ± 77.5 34.4 ± 44.6 53.2 ± 72.2 43.0±59.8
Ratio 3.6 2.0 1.5 1.8
IgE Der f (kUA/l) Pre-T 15.3 ± 20.9 19.0 ± 21.8 38.1 ± 79.4 25.5 ± 50.9
Post-T 61.3 ± 108.5 36.5 ± 49.3 56.7 ± 101.2 47.5 ± 79.3
Ratio 4.0 1.9 1.5 1.9
IgE nDer p 1 (kUA/l) Pre-T 6.0 ± 6.6 7.4 ± 6.4 9.9 ± 10.2 8.1 ± 8.0
Post-T 21.3 ± 30.1 19.8 ± 17.1 26.2 ± 22.1 22.4 ± 20.6
Ratio 3.8 2.7 2.6 2.8
IgE rDer p2 (kUA/l) Pre-T 12.1 ± 19.8 14.9 ± 22.3 35.8 ± 72.3 22.2 ± 47.2
Post-T 28.9 ± 52.8 24.0 ± 33.0 59.1 ± 103.1 38.1 ± 70.8
Ratio 2.4 1.6 1.7 1.7
IgG4 Der p (μg/l) Pre-T 62.1 ± 54.2 128.2 ± 92.5 142.4 ± 176.6 125.6 ± 126.4
Post-T 1923.0 ± 2656.3 2993.3 ± 3577.2 3961.0 ± 4862.4 3228.3 ± 3997.3
Ratio 27.8 23.3 27.8 25.7
IgG4 Der f (μg/l) Pre-T 67.1 ± 52.2 151.8 ± 161.2 152.1 ± 216.7 140.7 ± 174.0
Post-T 2445.8 ± 3552.9 2597.3 ±3340.4 3546.2 ± 4954.4 2942.8 ± 3986.7
Ratio 36.4 17.1 23.3 20.9
IgG4 nDer p1 (μg/l) Pre-T 17.3 ± 9.1 51.3 ± 75.1 36.0 ± 25.7 41.2 ± 55.9
Post-T 739.8 ± 732.3 2128.7 ± 3087.8 1470.9 ± 1406.2 1697.6 ± 2352.7
Ratio 42.8 41.5 40.9 41.2
IgG4 rDer p2 (μg/l) Pre-T 9.2 ± 12.1 45.2 ± 49.8 79.5 ± 139.0 53.1 ± 92.5
Post-T 1531.0 ± 2126.3 2039.8 ± 2165.6 3295.4 ± 4468.6 2457.5 ± 3245.3
Ratio 166.4 45.1 41.5 46.3
IgG nDer p1 (μg/l) Pre-T 620.0 ± 389.4 767.4 ±729.4 675.7 ± 384.6 714.2 ± 574.8
Post-T 2132 ± 1045.7 2835.3 ± 2095.1 2490.0 ± 1048.8 2612.3 ± 1631.2
Ratio 3.4 3.7 3.7 3.7
IgG rDer p2 (μg/l) Pre-T 674.0 ± 343.1 740.0 ± 529.4 715.7 ± 454.9 722.4 ± 471.4
Post-T 1986.0 ± 978.3 3241.1 ± 2155.4 4405.3 ± 2699.8 3527.9 ± 2375.9
Ratio 2.9 4.4 6.2 4.9
nDer = native Dermatophagoides pteronyssinus; rDer = recombinant Dermatophagoides pteronyssinus.
Pre-T = pre-treatment; Post-T = post-treatment; Ratio = Post/Pre-treatment ratio.
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treatment period.
Few studies have examined the effects of mite immuno-
therapy after approximately 3–4 months of treatment. A
study by Ibero et al. demonstrated clinical efficacy after 4
months of treatment with a modified HDM extract (cu-
mulative dose 216.75 μg) in asthmatic children by de-
creases in the allergen-induced airway and skin responses
[21]. In our study the cumulative allergoid doses ranged
from 346.8 to 467.5 μg, depending on the up-dosing regi-
men. Overall, the short-term treatment effects in our
study indicate an altered immune response following high
dose allergoid HDM immunotherapy, also affecting thelocal conjunctival allergic response. Obviously, these data
need confirmation in extended placebo-controlled studies,
currently ongoing.Conclusions
In conclusion, results of this study showed that updosing
towards a maintenance dose of 40,000 AUeq in 6 weekly
injections with allergoid HDM immunotherapy was
overall safe and well tolerated. In addition, there were
early signs of potential treatment effect already after 4
months of treatment. These results warrant future dose-
finding efficacy studies.
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